0.85
+0.0313(+3.82%)
Currency In USD
| Previous Close | 0.82 |
| Open | 0.82 |
| Day High | 0.85 |
| Day Low | 0.8 |
| 52-Week High | 3.85 |
| 52-Week Low | 0.57 |
| Volume | 73,607 |
| Average Volume | 46,550 |
| Market Cap | 13,861 |
| PE | -0.33 |
| EPS | -2.58 |
| Moving Average 50 Days | 1.02 |
| Moving Average 200 Days | 1.16 |
| Change | 0.03 |
If you invested $1000 in Akari Therapeutics, Plc (AKTX) 10 years ago, it would be worth $2.17 as of September 08, 2025 at a share price of $0.85. Whereas If you bought $1000 worth of Akari Therapeutics, Plc (AKTX) shares 5 years ago, it would be worth $26.9 as of September 08, 2025 at a share price of $0.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 05, 2025 10:45 AM GMT
BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and Chief
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
GlobeNewswire Inc.
Sep 03, 2025 12:30 PM GMT
Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event here BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology p
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
GlobeNewswire Inc.
Aug 14, 2025 1:15 PM GMT
Live video webcast on Tuesday, August 19th at 2:00 PM ETBOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology paylo